You need JavaScript to view this

Hypofractionated stereotactic radiation therapy in three to five fractions for vestibular schwannoma

Abstract

The objective of this study was to retrospectively examine the outcomes of hypofractionated stereotactic radiation therapy in three to five fractions for vestibular schwannomas. Twenty-five patients with 26 vestibular schwannomas were treated with hypofractionated stereotactic radiation therapy using a CyberKnife. The vestibular schwannomas of 5 patients were associated with type II neurofibromatosis. The median follow-up time was 80 months (range: 6-167); the median planning target volume was 2.6 cm{sup 3} (0.3-15.4); and the median prescribed dose ({>=}D90) was 21 Gy in three fractions (18-25 Gy in three to five fractions). Progression was defined as {>=}2 mm 3-dimensional post-treatment tumor enlargement excluding transient expansion. Progression or any death was counted as an event in progression-free survival rates, whereas only progression was counted in progression-free rates. The 7-year progression-free survival and progression-free rates were 78 and 95%, respectively. Late adverse events ({>=}3 months) with grades based on Common Terminology Criteria for Adverse Events, v4.03 were observed in 6 patients: Grade 3 hydrocephalus in one patient, Grade 2 facial nerve disorders in two and Grade 1-2 tinnitus in three. In total, 12 out of 25 patients maintained pure tone averages {<=}50 dB before hypofractionated stereotactic radiation therapy, and 6 of these 12 patients  More>>
Authors:
Morimoto, Masahiro; Yoshioka, Yasuo; [1]  Kotsuma, Tadayuki; [2]  others, and
  1. Osaka Univ., Graduate School of Medicine, Suita, Osaka (Japan)
  2. Kinki-chuo Chest Medical Center, Sakai, Osaka (Japan)
Publication Date:
Aug 15, 2013
Product Type:
Journal Article
Resource Relation:
Journal Name: Japanese Journal of Clinical Oncology; Journal Volume: 43; Journal Issue: 8
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ABSORBED RADIATION DOSES; FRACTIONATED IRRADIATION; GY RANGE 10-100; LINEAR ACCELERATORS; NEOPLASMS; PATIENTS; RADIOTHERAPY; SURVIVAL CURVES; VESTIBULAR APPARATUS; X RADIATION
OSTI ID:
22145373
Country of Origin:
Japan
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 0368-2811; TRN: JP1304618100002
Submitting Site:
INIS
Size:
page(s) 805-812
Announcement Date:
Nov 07, 2013

Citation Formats

Morimoto, Masahiro, Yoshioka, Yasuo, Kotsuma, Tadayuki, and others, and. Hypofractionated stereotactic radiation therapy in three to five fractions for vestibular schwannoma. Japan: N. p., 2013. Web. doi:10.1093/jjco/hyt082.
Morimoto, Masahiro, Yoshioka, Yasuo, Kotsuma, Tadayuki, & others, and. Hypofractionated stereotactic radiation therapy in three to five fractions for vestibular schwannoma. Japan. doi:10.1093/jjco/hyt082.
Morimoto, Masahiro, Yoshioka, Yasuo, Kotsuma, Tadayuki, and others, and. 2013. "Hypofractionated stereotactic radiation therapy in three to five fractions for vestibular schwannoma." Japan. doi:10.1093/jjco/hyt082. https://www.osti.gov/servlets/purl/10.1093/jjco/hyt082.
@misc{etde_22145373,
title = {Hypofractionated stereotactic radiation therapy in three to five fractions for vestibular schwannoma}
author = {Morimoto, Masahiro, Yoshioka, Yasuo, Kotsuma, Tadayuki, and others, and}
abstractNote = {The objective of this study was to retrospectively examine the outcomes of hypofractionated stereotactic radiation therapy in three to five fractions for vestibular schwannomas. Twenty-five patients with 26 vestibular schwannomas were treated with hypofractionated stereotactic radiation therapy using a CyberKnife. The vestibular schwannomas of 5 patients were associated with type II neurofibromatosis. The median follow-up time was 80 months (range: 6-167); the median planning target volume was 2.6 cm{sup 3} (0.3-15.4); and the median prescribed dose ({>=}D90) was 21 Gy in three fractions (18-25 Gy in three to five fractions). Progression was defined as {>=}2 mm 3-dimensional post-treatment tumor enlargement excluding transient expansion. Progression or any death was counted as an event in progression-free survival rates, whereas only progression was counted in progression-free rates. The 7-year progression-free survival and progression-free rates were 78 and 95%, respectively. Late adverse events ({>=}3 months) with grades based on Common Terminology Criteria for Adverse Events, v4.03 were observed in 6 patients: Grade 3 hydrocephalus in one patient, Grade 2 facial nerve disorders in two and Grade 1-2 tinnitus in three. In total, 12 out of 25 patients maintained pure tone averages {<=}50 dB before hypofractionated stereotactic radiation therapy, and 6 of these 12 patients (50%) maintained pure tone averages at this level at the final audiometric follow-up after hypofractionated stereotactic radiation therapy. However, gradient deterioration of pure tone average was observed in 11 of these 12 patients. The mean pure tone averages before hypofractionated stereotactic radiation therapy and at the final follow-up for the aforementioned 12 patients were 29.8 and 57.1 dB, respectively. Treating vestibular schwannomas with hypofractionated stereotactic radiation therapy in three to five fractions may prevent tumor progression with tolerable toxicity. However, gradient deterioration of pure tone average was observed. (author)}
doi = {10.1093/jjco/hyt082}
journal = {Japanese Journal of Clinical Oncology}
issue = {8}
volume = {43}
journal type = {AC}
place = {Japan}
year = {2013}
month = {Aug}
}